Novel Evidence That Neuroblastoma and Rhabdomyosarcoma, Two Types of Small Round Blue Cell Tumors, Frequently Infiltrate Bone Marrow and Express Functional Erythropoietin Receptor (EpoR)—therapeutic Implications

Author:

Poniewierska-Baran Agata12,Schneider Gabriela3,Ratajczak Janina1,Kucia Magdalena3,Ratajczak Mariusz Z1

Affiliation:

1. University of Louisville, Louisville, KY

2. Pomeranian medcial University, Szczecin, Poland

3. Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY

Abstract

Abstract Background : The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some solid tumors, and recently our group demonstrated the presence of functional EpoR on human and murine germline-derived cell lines, including teratocarcinomas and ovarian cancer cells (J Ovarian Res. 2014 Jun 17;7:66). Neuroblastoma (NRB) and rhabdomyosarcoma (RMS), the most common soft-tissue sarcomas of adolescents and children and described as “small round blue cell tumors”, frequently infiltrate the BM to such a degree that they mimic acute lymphoblastic leukemia. These tumors express several cancer testis antigens (CTAs), which are characteristic of germline-derived cells. This is intriguing because of the 150-year-old “embryonic rest hypothesis of cancer development” by Rudolf Virchow and Julius Conheim, in which malignancies may develop from dormant embryonic/germ cells residing in adult tissues. Small round blue cell tumors, including in NRB and RMS, are potential candidates for such malignancies. Hypothesis . Based on our observations that germline-derived tumors express functional EpoR and that NRB and RMS express CTAs, we asked whether these pediatric sarcomas express functional EpOR as well. Materials and Methods . In our studies we employed four human NRB, eight RMS cell lines (4 embryonal-type RMS cell lines and 4 alveolar-type RMS cell lines), and mRNA samples obtained from patients. Expression of EpoR was evaluated by RT-PCR and FACS. The functionality of EpoR in NRB and RMS cell lines was evaluated by chemotaxis, adhesion, and direct cell proliferation assays. In some of the experiments, RMS and NRB cells were exposed to vincristine (VCR) in the presence or absence of EpO to test whether EpO may impair the therapeutic effect of VCR. Results . We found expression of EpoR mRNA in all tested cell lines and patient samples. Importantly, EpoR has been found to be functional in all NRB and RMS cell lines tested, responding to stimulation by erythropoietin (EPO) by an increase in chemotaxis, adhesion, and phosphorylation of MAPKp42/44 and AKT. Moreover, we found that EPO stimulates proliferation of NRB and RMS cells and increases their resistance to VCR. Conclusions . Our data for the first time indicates that human pediatric sarcomas express functional EpoR. This finding has important clinical implications, as EPO is frequently employed to ameliorate chemotherapy-related anemia. The presence of functional EpoR on pediatric sarcoma cells indicates that EPO supplementation may have the unwanted side effect of tumor progression. Finally, the presence of functional EpoR on both NRB and RMS cells and germline-derived tumors as well as expression of CTA antigens by these cells supports the hypothesis that pediatric sarcomas may develop in developing tissues from embryonic remnants with germline potential. Disclosures No relevant conflicts of interest to declare.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3